Nuclear matrix protein fluid assay
    23.
    发明授权
    Nuclear matrix protein fluid assay 失效
    核基质蛋白液测定

    公开(公告)号:US5840503A

    公开(公告)日:1998-11-24

    申请号:US444821

    申请日:1995-05-18

    摘要: Disclosed is a method for evaluating the efficacy of a therapy associated with cell death in a patient undergoing such a therapy. The method involves providing at least two body fluid samples drawn from the patient, wherein a second sample is drawn from the patient after a first sample, and measuring the quantity per unit volume of a body-fluid soluble interior nuclear matrix protein in each of the samples. By comparing the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the first sample with the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the second sample, it is possible to determine whether there has been an increase or decrease of cell death in the patient during therapy.

    摘要翻译: 公开了一种用于评估在接受这种治疗的患者中与细胞死亡相关的疗法的功效的方法。 该方法包括提供从患者抽取的至少两个体液样品,其中在第一样品之后从患者抽出第二样品,并测量每个体液溶液内核核基质蛋白的每单位体积的量 样品。 通过比较第一样品中体液可溶性内部核基质蛋白的单位体积量与第二样品中体液可溶性内部核基质蛋白的单位体积量,可以确定是否存在 是治疗期间患者细胞死亡的增加或减少。